Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| 5T4 mAb - 01 | Lead | Solid Tumor | Ovarian cancer,Lung cancer |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CHEK-ATP176 | Human | HEK293/Human TPBG Stable Cell Line | |||
| TPG-R52H6 | Rat | Rat TPBG / 5T4 Protein, His Tag (MALS verified) |  |
|
|
| TPG-M5255 | Mouse | Mouse TPBG / 5T4 Protein, Fc Tag (MALS verified) |  |
|
|
| TPG-H82F6 | Human | Biotinylated Human TPBG / 5T4 protein, Fc,Avitag™ (MALS verified) |  |
|
|
| TPG-C52H3 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque TPBG / 5T4 Protein, His Tag |  |
|
|
| TPG-M52H3 | Mouse | Mouse TPBG / 5T4 Protein, His Tag (MALS verified) |  |
|
|
| TPG-H5253 | Human | Human TPBG / 5T4 Protein, Fc Tag (MALS verified) |  |
|
|
| TPG-H52E5 | Human | Unconjugated Human TPBG / 5T4 Protein, His,Avitag™ |  |
|
|
| TPG-H82Eb | Human | Biotinylated Human TPBG / 5T4 Protein, His,Avitag™ |  |
|
|
Expression analysis of human TPBG on HEK293/Human TPBG Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human TPBG Stable Cell Line or negative control cell using anti-human TPBG antibody followed by staining with PE anti-human IgG antibody.
Immobilized Cynomolgus / Rhesus macaque TPBG, His Tag (Cat. No. TPG-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-TPBG Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Rat TPBG Protein, His Tag (Cat. No. TPG-R52H6) is more than 90% and the molecular weight of this protein is around 42-57 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Naptumomab estafenatox | TTS-CD3; ABR-217620 | Phase 2 Clinical | Active Biotech Ab | Carcinoma, Renal Cell; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| ALG.APV-527 | ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 | Phase 2 Clinical | Aptevo, Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| OXB-301 | OXB-301; SAR-109659 | Phase 2 Clinical | Oxford Biomedica | Ovarian Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| SYD-1875 | SYD-1875 | Phase 1 Clinical | Synthon Bv | Solid tumours | Details |
| ASN-004 | ASN-004 | Phase 1 Clinical | Asana Biosciences Llc | Solid tumours | Details |
| ACR-246 | ACR246; ACR-246 | Phase 1 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Solid tumours | Details |
| FTL-008.16 | FTL-008.16; FTL008.16 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd | Solid tumours | Details |
| IBR-854 | IBR854; IBR-854 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours; Neoplasms | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-5T4 CAR-raNK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details | |
| Prostate cancer vaccine(inactivated viral)(University of Oxford) | Clinical | University Of Oxford | Prostatic Neoplasms | Details | |
| Naptumomab estafenatox | TTS-CD3; ABR-217620 | Phase 2 Clinical | Active Biotech Ab | Carcinoma, Renal Cell; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| ALG.APV-527 | ALG-APV-527; ADC-1016; ATOR-1016; ALG.APV-527 | Phase 2 Clinical | Aptevo, Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
| OXB-301 | OXB-301; SAR-109659 | Phase 2 Clinical | Oxford Biomedica | Ovarian Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| SYD-1875 | SYD-1875 | Phase 1 Clinical | Synthon Bv | Solid tumours | Details |
| ASN-004 | ASN-004 | Phase 1 Clinical | Asana Biosciences Llc | Solid tumours | Details |
| ACR-246 | ACR246; ACR-246 | Phase 1 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Solid tumours | Details |
| FTL-008.16 | FTL-008.16; FTL008.16 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd | Solid tumours | Details |
| IBR-854 | IBR854; IBR-854 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours; Neoplasms | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-5T4 CAR-raNK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details | |
| Prostate cancer vaccine(inactivated viral)(University of Oxford) | Clinical | University Of Oxford | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
